+ Site Statistics
References:
52,572,879
Abstracts:
28,705,754
PMIDs:
27,750,366
DOIs:
25,464,004
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor



Oral ezatiostat HCl (Telintra®, TLK199) and idiopathic chronic neutropenia (ICN): a case report of complete response of a patient with G-CSF resistant ICN following treatment with ezatiostat, a glutathione S-transferase P1-1 (GSTP1-1) inhibitor



Journal of Hematology and Oncology 4: 43



Idiopathic chronic neutropenia (ICN) describes a heterogeneous group of hematologic diseases characterized by low circulating neutrophil levels often associated with recurrent fevers, chronic mucosal inflammation, and severe systemic infections. The severity and risk of complications, including serious infections, are inversely proportional to the absolute neutrophil count (ANC), with the greatest problems occurring in patients with an ANC of less than 0.5 × 109/L. This case report describes a 64-year-old female with longstanding rheumatoid arthritis who subsequently developed ICN with frequent episodes of sepsis requiring hospitalization and prolonged courses of antibiotics over a 4-year period. She was treated with granulocyte colony stimulating factors (G-CSF) but had a delayed, highly variable, and volatile response. She was enrolled in a clinical trial evaluating the oral investigational agent ezatiostat. Ezatiostat, a glutathione S-transferase P1-1 inhibitor, activates Jun kinase, promoting the growth and maturation of hematopoietic progenitor stem cells. She responded by the end of the first month of treatment with stabilization of her ANC (despite tapering and then stopping G-CSF), clearing of fever, and healing of areas of infection. This ANC response to ezatiostat treatment has now been sustained for over 8 months and continues. These results suggest potential roles for ezatiostat in the treatment of patients with ICN who are not responsive to G-CSF, as an oral therapy alternative, or as an adjunct to G-CSF, and further studies are warranted.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 054781665

Download citation: RISBibTeXText

PMID: 22047626

DOI: 10.1186/1756-8722-4-43


Related references

Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome. Journal of Hematology and Oncology 2: 20, 2010

Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure. Journal of Hematology and Oncology 3: 16, 2010

Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 113(26): 6533-6540, 2009

Induced monocytic differentiation in an HL60 cell line resistant to the glutathione S-transferase inhibitor TLK199. Proceedings of the American Association for Cancer Research Annual Meeting 42: 187-188, March, 2001

Phase 1 dose escalation study of TLK199 tablets (Telintra), a novel glutathione analog, in myelodysplastic syndrome. 2007

Ezatiostat hydrochloride for the treatment of myelodysplastic syndromes. Expert Opinion on Investigational Drugs 24(5): 725-733, 2016

Involvement of c-Jun NH2-terminal kinase in the myelostimulant properties of the glutathione s-transferase pi inhibitor TLK199. Proceedings of the American Association for Cancer Research Annual Meeting 44: 1313, July, 2003

A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome. Cancer 118(8): 2138-2147, 2012

Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. Cancer Research 61(24): 8611-8616, 2001

Phenotypic analysis of blood neutrophils in a patient with chronic idiopathic neutropenia and favorable response to G-CSF treatment. American Journal of Hematology 51(1): 96-97, 1996

A tyrosine-reactive irreversible inhibitor for glutathione S-transferase Pi (GSTP1). Molecular Biosystems 12(6): 1768-1771, 2017

Association between glutathione-S-transferase gene polymorphisms (GSTM1, GSTT1 and GSTP1) and idiopathic azoospermia. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 30(1): 102-105, 2013

Evaluation of Genetic Polymorphisms in Glutathione S-Transferase Theta1, Glutathione S-Transferase Mu1, and Glutathione S-Transferase Mu3 in Oral Leukoplakia and Oral Squamous Cell Carcinoma with Deleterious Habits using Polymerase Chain Reaction. International Journal of Applied and Basic Medical Research 7(3): 181-185, 2017

Association of polymorphisms in glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) with idiopathic azoospermia or oligospermia in Sichuan, China. Asian Journal of Andrology 17(3): 481-486, 2016

Association between glutathione-S-transferase GSTP1 genotypes, GSTP1 over-expression, and outcome in epithelial ovarian cancer. International Journal of Gynecological Cancer 14(2): 242-250, 2004